Filtered By:
Specialty: Cardiology
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 800 results found since Jan 2013.
First clinical experiences with inclisiran in real world setting
Background and Aims: Inclisiran is the first-in-class small interfering RNA (siRNA) PCSK9 inhibitor. In clinical trials, inclisiran showed effective and sustained LDL-C reduction. However, data about the efficacy and safety in clinical setting are not available yet. We aim to investigate this in high-risk patients with FH and or ASCVD in clinical practice.
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: A. Galema-Boers, J. Mulder, K. Steward, J. Roeters Van Lennep Source Type: research
Current LDL-C management in Germany – The Victorion-implement study
Background and Aims: The VICTORION-Implement study aims to characterize the LDL-C management in patients with atherosclerotic cardiovascular disease (ASCVD) initiating a new oral lipid lowering therapy (LLT) or the PSCK9 siRNA inclisiran. The study assesses clinical characteristics, utilization of healthcare resources and patient reported outcomes.
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: O. Weing ärtner, U. Laufs, S. Lorkowski, B. Rauser, R. Etzl, V. Schettler Source Type: research
miR-145 Alleviates Smooth Muscle Cell Phenotype Transition via ADAM17-Mediated ACE2 Shedding
In conclusion, miR-145 alleviates phenotype transition from contractile to synthetic type via ADAM17-mediated ACE2 shedding in VSMCs and retains the activation of ACE2-Ang-(1-7)-Mas axis, which may benefit the vascular structural remodeling in the metabolic hypertension.PMID:37521117 | PMC:PMC10374374 | DOI:10.1155/2023/9497716
Source: International Journal of Hypertension - July 31, 2023 Category: Cardiology Authors: Juan Wen Baiyi Tang Lan Guo Wei Chen Xiaohong Tang Source Type: research
SGLT2 inhibitor canagliflozin alleviates vascular calcification through suppression of NLRP3 inflammasome
CONCLUSIONS: Our study for the first time demonstrates that CANA exerts a protective effect on vascular calcification at least partially via suppressing NLRP3 signaling pathway. Therefore, supplementation of CANA as well as inhibition of NLRP3 inflammasome presents a potential therapy for vascular calcification.PMID:37523743 | DOI:10.1093/cvr/cvad119
Source: Atherosclerosis - July 31, 2023 Category: Cardiology Authors: An Chen Zirong Lan Li Li Luting Xie Xiaoyu Liu Xiulin Yang Siyi Wang Qingchun Liang Qianqian Dong Liyun Feng Yining Li Yuanzhi Ye Mingwei Fu Lihe Lu Jianyun Yan Source Type: research
miR-145 Alleviates Smooth Muscle Cell Phenotype Transition via ADAM17-Mediated ACE2 Shedding
In conclusion, miR-145 alleviates phenotype transition from contractile to synthetic type via ADAM17-mediated ACE2 shedding in VSMCs and retains the activation of ACE2-Ang-(1-7)-Mas axis, which may benefit the vascular structural remodeling in the metabolic hypertension.PMID:37521117 | PMC:PMC10374374 | DOI:10.1155/2023/9497716
Source: International Journal of Hypertension - July 31, 2023 Category: Cardiology Authors: Juan Wen Baiyi Tang Lan Guo Wei Chen Xiaohong Tang Source Type: research
